For most of the last century, cancer research has been dominated by one guiding idea: that tumors arise from an accumulation of genetic mutations. This somatic mutation theory has shaped diagnosis, drug development, and treatment planning for decades. But a parallel line of research — one rooted in metabolism rather than genetics — has been quietly gaining traction, and with it, a renewed scientific interest in the role nutrition plays in cancer care.
The Metabolic Roots of Cancer: From Warburg to Seyfried
The story begins nearly a century ago. In the 1920s, German biochemist Otto Warburg observed something unusual: cancer cells generate energy primarily through fermentation of glucose, even when oxygen is abundant. Healthy cells, by contrast, rely on oxidative phosphorylation — a far more efficient, oxygen-based process occurring in the mitochondria. This phenomenon, now known as the Warburg effect, earned Warburg a Nobel Prize and became the biochemical basis for PET imaging, which detects tumors by tracking their abnormally high glucose uptake.
For decades, Warburg’s observation was treated as a side effect of cancer rather than a cause. That changed with the work of Thomas N. Seyfried, a biology professor at Boston College, who spent much of his career arguing that mitochondrial dysfunction is not incidental to cancer — it may be central to it. In his book Cancer as a Metabolic Disease and in numerous peer-reviewed papers, Seyfried proposed that damaged mitochondrial respiration forces tumor cells to depend heavily on fermenting two fuels: glucose, through glycolysis, and the amino acid glutamine, through glutaminolysis.
This idea evolved into what Seyfried and colleagues termed the “press-pulse” strategy: combining a sustained metabolic stressor, such as a ketogenic diet or calorie restriction, with acute interventions like hyperbaric oxygen therapy or metabolically targeted drugs. It’s worth noting that Seyfried’s metabolic theory remains a minority position relative to the dominant genetic model of oncogenesis — it has generated valuable hypotheses and active debate, but it has not replaced the standard of care in mainstream oncology.
Putting the Theory to the Test: The ChemoThermia Experience
Nowhere has this framework been applied more systematically in a clinical setting than at the ChemoThermia Oncology Center in Istanbul, Turkey, founded in 2010 by Dr. Mehmet Salih İyikesici and colleagues. The clinic developed an approach it calls Metabolically Supported Chemotherapy (MSCT): standard chemotherapy drugs are administered following induced hypoglycemia, combined with a ketogenic diet, hyperthermia, and hyperbaric oxygen therapy. Seyfried himself has co-authored several of the papers published by the ChemoThermia team.
Over the past decade, the center has published case reports and retrospective studies describing outcomes in patients with advanced or metastatic disease — including one widely cited case of a woman with end-stage, heavily metastasized breast cancer who reportedly achieved a complete and durable response.
These findings deserve attention, but also caution. Case reports and single-center retrospective studies sit near the bottom of the evidence hierarchy: they lack control groups and cannot establish that the metabolic intervention — rather than the chemotherapy itself or natural disease variability — caused the outcome. No randomized controlled trial has yet tested MSCT against standard chemotherapy alone.
Mediterranean Diet, Fasting, and Established Cancer Nutrition Guidelines
While the metabolic theory occupies the frontier of cancer nutrition research, a much larger and more mainstream body of evidence supports a different, less dramatic message: that everyday nutritional care measurably improves outcomes for people with cancer.
The European Society for Clinical Nutrition and Metabolism (ESPEN) guidelines recommend that most patients maintain — not restrict — their energy intake and consume adequate protein to counter cachexia, the muscle-wasting syndrome that affects an estimated 25–80% of cancer patients. Large meta-analyses also link high adherence to the Mediterranean dietary pattern with meaningfully lower all-cause mortality in cancer survivors. And a growing number of randomized pilot trials have tested short-term fasting around chemotherapy infusions, finding it feasible and associated with improved quality of life in some patients.
Where This Leaves Patients and Clinicians
Taken together, the research paints a layered picture. At one level, there is strong, well-established evidence that nutritional screening and dietary patterns like the Mediterranean diet meaningfully support patients through cancer treatment. At another, more exploratory level, the metabolic theory of cancer represents an active and legitimate area of scientific inquiry, still awaiting the controlled, large-scale trials needed to confirm its place in standard care.
For patients and families navigating a cancer diagnosis, the practical takeaway is to bring nutrition into the conversation with the oncology care team from day one — and to treat any ketogenic, fasting, or metabolically targeted protocol as something to pursue only under close medical supervision.
Have questions about nutrition during your treatment? [Contact Dr. Schirippa] or explore our Oncology Nutrition Consultation.
Have questions about nutrition during your cancer treatment? Explore our Oncology Nutrition Consultation to get started.